Recurrent Skin Carcinoma (DBCOND0060371)
Identifiers
- Synonyms
- Not Available
Associated Data
- Indicated Drugs and Targets
- Not Available
- Clinical Trials
Identifier Title Drug(s) Purpose Phase Status NCT02465060 Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) - ABSK-091
- Adavosertib
- Afatinib
- Binimetinib
- Capivasertib
- Copanlisib
- Crizotinib
- Dabrafenib
- Dasatinib
- Defactinib
- Erdafitinib
- GSK-2636771
- Ipatasertib
- Larotrectinib
- Methane
- Nivolumab
- Osimertinib
- Palbociclib
- Pertuzumab
- Relatlimab
- Sapanisertib
- Sulfate ion
- Sunitinib
- Taselisib
- Trametinib
- Trastuzumab
- Trastuzumab emtansine
- Tyrosine
- Ulixertinib
- Vismodegib
screening 2 active_not_recruiting NCT00954226 Phase Ib Study of Erlotinib Prior to Surgery in Patients with Head and Neck Cancer treatment 1 active_not_recruiting NCT02318771 Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer treatment 1 completed NCT02964559 Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer treatment 2 completed NCT01727076 Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer treatment 1 completed